News & Updates
Filter by Specialty:
Is docetaxel helpful in metastatic hormone-sensitive prostate cancer?
Treatment with docetaxel appears beneficial in patients with low- and high-burden metastatic hormone-sensitive prostate cancer, a study has shown. However, no consistent differences for overall survival are seen in subgroup analyses as regards volume of metastatic disease.
Is docetaxel helpful in metastatic hormone-sensitive prostate cancer?
02 Dec 2021
Overall survival in metastatic renal cell carcinoma differs by race, gender, treatment
Among patients with metastatic renal cell carcinoma, there are multiple factors that affect overall survival, including race, gender, treatment, and socioeconomic factors, as reported in a study.
Overall survival in metastatic renal cell carcinoma differs by race, gender, treatment
01 Dec 2021
Childhood cancers often misdiagnosed as TB, leads to more deaths
Cancer is frequently misdiagnosed as tuberculosis (TB) in children due to the clinical and radiologic overlap of the two diseases, which then contributes to increased mortality in this population, reveals a recent study.
Childhood cancers often misdiagnosed as TB, leads to more deaths
30 Nov 2021
Exercise superior to usual care at reducing upper limb disability after breast cancer surgery
An early, structured, progressive exercise is safe and effective for women at high risk of developing shoulder and upper limb problems following nonreconstructive breast cancer surgery, evidence from the UK PROSPER study shows.
Exercise superior to usual care at reducing upper limb disability after breast cancer surgery
29 Nov 2021
Psoriasis ups risk of colorectal cancer
Patients with psoriasis appear to be at greater risk for developing colorectal cancer, suggests a recent study, noting how gastroenterology consultation and colonoscopic examination are indicated for such individuals presenting with bowel symptoms.
Psoriasis ups risk of colorectal cancer
26 Nov 2021
6 months of adjuvant trastuzumab noninferior to 12 months in HER2-positive early breast cancer
Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage breast cancer, according to results from an individual patient data (IPD) meta-analysis of five noninferiority randomized controlled trials (RCTs) presented at the European Society for Medical Oncology (ESMO) Congress 2021.